Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 8/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 7/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 7/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.39 |
| ▸ | ANO2 | Q9NQ90 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5650131 | 0.88 | F2 (0.52) | F2PRSS1PRSS2PRSS3SMN1; SMN2 | |
| SCHEMBL5650866 | 0.87 | F2 (0.51) | F2PRSS1PRSS2PRSS3SMN1; SMN2 | |
| SCHEMBL5647938 | 0.86 | F2 (0.49) | F2PRSS1PRSS2PRSS3SMN1; SMN2 | |
| SCHEMBL5648385 | 0.86 | F2 (0.51) | F2PRSS1PRSS2PRSS3SMN1; SMN2 | |
| SCHEMBL5651509 | 0.85 | F2 (0.54) | F2PRSS1PRSS2PRSS3SMN1; SMN2 | |
| SCHEMBL5649308 | 0.85 | F2 (0.52) | F2PRSS1PRSS2PRSS3SMN1; SMN2 | |
| SCHEMBL5646063 | 0.85 | F2 (0.52) | F2PRSS1PRSS2PRSS3SMN1; SMN2 | |
| SCHEMBL5652489 | 0.84 | F2 (0.52) | F2PRSS1PRSS2PRSS3SMN1; SMN2 | |
| SCHEMBL5650742 | 0.84 | F2 (0.51) | F2PRSS1PRSS2PRSS3SMN1; SMN2 | |
| SCHEMBL5645368 | 0.84 | P2RX7 (0.48) | F2PRSS1P2RX7CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161643-A1 | Pyridin-2-one compounds useful as inhibitors of thrombin | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| EP-1713774-A1 | NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005075424-A1 | NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161643-A1 | Pyridin-2-one compounds useful as inhibitors of thrombin | PLG, F2, PLAT | F2 2/4885PRSS1 20/4885PRSS2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.